An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium

被引:0
作者
Koneswarakantha, Bjoern [1 ]
Adyanthaya, Ronojit [2 ]
Emerson, Jennifer [3 ]
Collin, Frederik [3 ]
Keller, Annett [4 ]
Mattheus, Michaela [4 ]
Spyroglou, Ioannis [2 ]
Donevska, Sandra [2 ]
Menard, Timothe [1 ]
机构
[1] F Hoffmann La Roche & Cie AG, CH-4070 Basel, Switzerland
[2] Merck & Co Inc, Rahway, NJ 07065 USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach, Germany
[4] Boehringer Ingelheim Pharm GmbH & Co, D-55216 Ingelheim, Germany
关键词
Quality assurance; Open-source; Analytics; GCP; Validation; Transparency;
D O I
10.1007/s43441-024-00631-8
中图分类号
R-058 [];
学科分类号
摘要
Accurate and timely reporting of adverse events (AEs) in clinical trials is crucial to ensuring data integrity and patient safety. However, AE under-reporting remains a challenge, often highlighted in Good Clinical Practice (GCP) audits and inspections. Traditional detection methods, such as on-site investigator audits via manual source data verification (SDV), have limitations. Addressing this, the open-source R package {simaerep} was developed to facilitate rapid, comprehensive, and near-real-time detection of AE under-reporting at each clinical trial site. This package leverages patient-level AE and visit data for its analyses. To validate its efficacy, three member companies from the Inter coMPany quALity Analytics (IMPALA) consortium independently assessed the package. Results showed that {simaerep} consistently and effectively identified AE under-reporting across all three companies, particularly when there were significant differences in AE rates between compliant and non-compliant sites. Furthermore, {simaerep}'s detection rates surpassed heuristic methods, and it identified 50% of all detectable sites as early as 25% into the designated study duration. The open-source package can be embedded into audits to enable fast, holistic, and repeatable quality oversight of clinical trials.
引用
收藏
页码:591 / 599
页数:9
相关论文
共 21 条
  • [1] [Anonymous], 2023, EMBEDDING OPEN SOURC
  • [2] Ferreira JA., 2007, Int. J. Biostat, V3, DOI DOI 10.2202/1557-4679.1065
  • [3] Estimation of the Youden index and its associated cutoff point
    Fluss, R
    Faraggi, D
    Reiser, B
    [J]. BIOMETRICAL JOURNAL, 2005, 47 (04) : 458 - 472
  • [4] Food and Drug Administration, 2015, WARN LETT AB SCI
  • [5] Food and Drug Administration, 2009, GUID IND INV RESP PR
  • [6] Food and Drug Administration, CLIN INV INSP LIST C
  • [7] The characteristics of patient safety culture in Japan, Taiwan and the United States
    Fujita, Shigeru
    Seto, Kanako
    Ito, Shinya
    Wu, Yinghui
    Huang, Chiu-Chin
    Hasegawa, Tomonori
    [J]. BMC HEALTH SERVICES RESEARCH, 2013, 13
  • [8] Time-consuming and expensive data quality monitoring procedures persist in clinical trials: A national survey
    Houston, Lauren
    Martin, Allison
    Yu, Ping
    Probst, Yasmine
    [J]. CONTEMPORARY CLINICAL TRIALS, 2021, 103
  • [9] International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2021, E8 R1 GUID GEN CONS
  • [10] International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2016, E6 R2 GUID GOOD CLIN